Alpha Cognition announced that the United States Patent and Trademark Office, USPTO, published U.S. Patent Application No. 19/090,242, titled "Process for Preparing Benzgalantamine and Salts Thereof," on October 1, 2026, as U.S. Patent Application Publication No. US 2026/0297103 A1. The published patent application covers Alpha Cognition's proprietary manufacturing technology for benzgalantamine, the active ingredient in ZUNVEYL. The application includes innovations designed to improve manufacturing efficiency, product quality, impurity control and production scalability, while also covering the preparation of benzgalantamine salts and related pharmaceutical compositions.

8/13 16:30

Alpha Cognition Q2 Revenue at $6M, Below Consensus

Reports Q2 revenue $6M, consensus $6.11M. "We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "Our commercial team continues to execute effectively, expanding the prescriber base while driving deeper utilization within existing accounts. We are particularly encouraged by the growth in repeat prescribers, long-term care facility adoption and monthly prescription demand, which we believe reflects increasing clinical confidence in ZUNVEYL. Its differentiated profile and growing real-world utilization provide a strong foundation for continued growth."

8/3 10:30

Alpha Cognition Inc Trading Halted Due to Volatility Trading Pause

Alpha Cognition Inc trading halted, volatility trading pause

7/29 09:00

Alpha Cognition Secures European Patent for ZUNVEYL

Alpha Cognition announced that the European Patent Office, EPO, has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer's disease. The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition's global intellectual property portfolio and may provide additional patent protection for benzgalantamine's pharmaceutical development and potential commercialization into 2042, subject to applicable patent requirements. "This European patent grant is another important step in our strategy to build broad intellectual property protection around benzgalantamine and ZUNVEYL as a differentiated treatment option for patients with mild-to-moderate Alzheimer's disease," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "By strengthening our IP position in Europe, we are continuing to support the long-term clinical and commercial potential of benzgalantamine."

6/23 09:00

Alpha Cognition Board Changes, Robert Wills Elected Chairman

Alpha Cognition announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. Wills has served on Alpha Cognition's Board of Directors since 2025, and currently serves as Chair of the Governance and Nominating Committee and as a member of the Audit Committee.

イベントをもっと見る

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。